Search clinical trials for: Nifurtimox (BAYA2502)

Total 17 results

Bayer

Completed

Study to Assess Bioequivalence of a New Nifurtimox Oral Tablet Formulation

Bioequivalence

Argentina
Bayer

Completed

Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients

Chagas Disease

Argentina
Bayer

Completed

Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients

Chagas Disease

Argentina
Bayer

Not yet recruiting

An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health

Chagas Disease

Spain, Germany, Argentina, Chile, United States, Bolivia, Uruguay, El Salvador, Guatemala, Honduras
Bayer

Completed

Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina

Chagas' Disease

Argentina
Bayer

Completed

Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg

Chagas Disease

Argentina
Bayer

Completed

Prospective Study of a Pediatric Nifurtimox Formulation for Chagas' Disease

Chagas Disease

Colombia, Argentina, Bolivia
Bayer

Completed

Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study

Chagas' Disease

Argentina
Drugs for Neglected Diseases
Swiss Tropical & Public Health Institute; Ministry of Public Health, Democratic...

Completed

Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase (NECT-FIELD)

Human African Trypanosomiasis

Congo
Epicentre
Médecins Sans Frontières, France

Terminated

Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda (NECS)

Trypanosomiasis, African

Uganda
University of Vermont
St. Louis University

Completed

Safety Study of Nifurtimox for Relapsed or Refractory Neuroblastoma

Neuroblastoma

United States
Epicentre
Médecins Sans Frontières, France; Embassy of France in Uganda; National Sleeping...

Terminated

Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis

Trypanosomiasis, African

Uganda
Drugs for Neglected Diseases
World Health Organization; Swiss Tropical & Public Health Institute; Epicentre; Medecins Sans Frontieres, Netherlands and other collaborators

Completed

Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis

Trypanosomiasis, African

Congo, The Democratic Republic of the, Congo
University of Texas, El Paso
National Institute of Allergy and Infectious Diseases (NIAID); Drugs for Neglected... and other collaborators

Active, not recruiting

New Therapies and Biomarkers for Chagas Infection (TESEO)

Chagas Disease | Trypanosoma Cruzi Infection

Bolivia
Drugs for Neglected Diseases

Completed

Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2

Sleeping Sickness | Human African Trypanosomiasis (HAT)

Central African Republic, Congo, The Democratic Republic of the, Congo
Universidad Autónoma de Bucaramanga
Fundación Cardioinfantil Instituto de Cardiología; Instituto Nacional de Salud... and other collaborators

Unknown

CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY) (CHICAMOCHA-3)

Chagas Disease

Colombia
Giselle Sholler
Bayer

Completed

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

Medulloblastoma | Neuroblastoma

United States

3

Subscribe